335 related articles for article (PubMed ID: 25515961)
1. MicroRNA-486 regulates normal erythropoiesis and enhances growth and modulates drug response in CML progenitors.
Wang LS; Li L; Li L; Chu S; Shiang KD; Li M; Sun HY; Xu J; Xiao FJ; Sun G; Rossi JJ; Ho Y; Bhatia R
Blood; 2015 Feb; 125(8):1302-13. PubMed ID: 25515961
[TBL] [Abstract][Full Text] [Related]
2. A 2-way miRror of red blood cells and leukemia.
Grimes HL; Meyer SE
Blood; 2015 Feb; 125(8):1202-3. PubMed ID: 25700423
[TBL] [Abstract][Full Text] [Related]
3. BCR-ABL1 mediated miR-150 downregulation through MYC contributed to myeloid differentiation block and drug resistance in chronic myeloid leukemia.
Srutova K; Curik N; Burda P; Savvulidi F; Silvestri G; Trotta R; Klamova H; Pecherkova P; Sovova Z; Koblihova J; Stopka T; Perrotti D; Polakova KM
Haematologica; 2018 Dec; 103(12):2016-2025. PubMed ID: 30049824
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA-139-5p regulates proliferation of hematopoietic progenitors and is repressed during BCR-ABL-mediated leukemogenesis.
Choi J; Kim YK; Park K; Nah J; Yoon SS; Kim DW; Kim VN; Seong RH
Blood; 2016 Oct; 128(17):2117-2129. PubMed ID: 27605510
[TBL] [Abstract][Full Text] [Related]
5. Aberrantly reduced expression of miR-342-5p contributes to CCND1-associated chronic myeloid leukemia progression and imatinib resistance.
Wu YY; Lai HF; Huang TC; Chen YG; Ye RH; Chang PY; Lai SW; Chen YC; Lee CH; Liu WN; Dai MS; Chen JH; Ho CL; Chiu YL
Cell Death Dis; 2021 Oct; 12(10):908. PubMed ID: 34611140
[TBL] [Abstract][Full Text] [Related]
6. De-regulated STAT5A/miR-202-5p/USP15/Caspase-6 regulatory axis suppresses CML cell apoptosis and contributes to Imatinib resistance.
Nie ZY; Yao M; Yang Z; Yang L; Liu XJ; Yu J; Ma Y; Zhang N; Zhang XY; Liu MH; Jiang LL; Luo JM
J Exp Clin Cancer Res; 2020 Jan; 39(1):17. PubMed ID: 31952546
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-486-5p is an erythroid oncomiR of the myeloid leukemias of Down syndrome.
Shaham L; Vendramini E; Ge Y; Goren Y; Birger Y; Tijssen MR; McNulty M; Geron I; Schwartzman O; Goldberg L; Chou ST; Pitman H; Weiss MJ; Michaeli S; Sredni B; Göttgens B; Crispino JD; Taub JW; Izraeli S
Blood; 2015 Feb; 125(8):1292-301. PubMed ID: 25533034
[TBL] [Abstract][Full Text] [Related]
8. microRNA-199a/b-5p enhance imatinib efficacy via repressing WNT2 signaling-mediated protective autophagy in imatinib-resistant chronic myeloid leukemia cells.
Chen PH; Liu AJ; Ho KH; Chiu YT; Anne Lin ZH; Lee YT; Shih CM; Chen KC
Chem Biol Interact; 2018 Aug; 291():144-151. PubMed ID: 29890129
[TBL] [Abstract][Full Text] [Related]
9. MiR-362-5p promotes the malignancy of chronic myelocytic leukaemia via down-regulation of GADD45α.
Yang P; Ni F; Deng RQ; Qiang G; Zhao H; Yang MZ; Wang XY; Xu YZ; Chen L; Chen DL; Chen ZJ; Kan LX; Wang SY
Mol Cancer; 2015 Nov; 14():190. PubMed ID: 26545365
[TBL] [Abstract][Full Text] [Related]
10. Molecular signature of CD34(+) hematopoietic stem and progenitor cells of patients with CML in chronic phase.
Diaz-Blanco E; Bruns I; Neumann F; Fischer JC; Graef T; Rosskopf M; Brors B; Pechtel S; Bork S; Koch A; Baer A; Rohr UP; Kobbe G; von Haeseler A; Gattermann N; Haas R; Kronenwett R
Leukemia; 2007 Mar; 21(3):494-504. PubMed ID: 17252012
[TBL] [Abstract][Full Text] [Related]
11. HDAC inhibitor suppresses proliferation and tumorigenicity of drug-resistant chronic myeloid leukemia stem cells through regulation of hsa-miR-196a targeting BCR/ABL1.
Bamodu OA; Kuo KT; Yuan LP; Cheng WH; Lee WH; Ho YS; Chao TY; Yeh CT
Exp Cell Res; 2018 Sep; 370(2):519-530. PubMed ID: 30017934
[TBL] [Abstract][Full Text] [Related]
12. Morin Inhibits Proliferation and Induces Apoptosis by Modulating the miR-188-5p/PTEN/AKT Regulatory Pathway in CML Cells.
Nie ZY; Yang L; Liu XJ; Yang Z; Yang GS; Zhou J; Qin Y; Yu J; Jiang LL; Wen JK; Luo JM
Mol Cancer Ther; 2019 Dec; 18(12):2296-2307. PubMed ID: 31515296
[TBL] [Abstract][Full Text] [Related]
13. Expression of the miR-17-92 polycistron in chronic myeloid leukemia (CML) CD34+ cells.
Venturini L; Battmer K; Castoldi M; Schultheis B; Hochhaus A; Muckenthaler MU; Ganser A; Eder M; Scherr M
Blood; 2007 May; 109(10):4399-405. PubMed ID: 17284533
[TBL] [Abstract][Full Text] [Related]
14. CRKL but not CRKII contributes to hemin-induced erythroid differentiation of CML.
Guo C; Lv X; Zhang Q; Yi L; Ren Y; Li Z; Yan J; Zheng S; Sun MZ; Liu S
J Cell Mol Med; 2024 May; 28(9):e18308. PubMed ID: 38683131
[TBL] [Abstract][Full Text] [Related]
15. miR-96 acts as a tumor suppressor via targeting the BCR-ABL1 oncogene in chronic myeloid leukemia blastic transformation.
Huang T; Fu Y; Wang S; Xu M; Yin X; Zhou M; Wang X; Chen C
Biomed Pharmacother; 2019 Nov; 119():109413. PubMed ID: 31518872
[TBL] [Abstract][Full Text] [Related]
16. MiRNA182 regulates percentage of myeloid and erythroid cells in chronic myeloid leukemia.
Arya D; Sachithanandan SP; Ross C; Palakodeti D; Li S; Krishna S
Cell Death Dis; 2017 Jan; 8(1):e2547. PubMed ID: 28079885
[TBL] [Abstract][Full Text] [Related]
17. Modulating the Growth and Imatinib Sensitivity of Chronic Myeloid Leukemia Stem/Progenitor Cells with Pullulan/MicroRNA Nanoparticles In Vitro.
Ma W; Liu J; Xie J; Zhang X; Zhou H; Yao H; Zhang W; Guo D; Zhu L; Xiao L; Wu D; Xu H; Chen S; Zhao Y
J Biomed Nanotechnol; 2015 Nov; 11(11):1961-74. PubMed ID: 26554155
[TBL] [Abstract][Full Text] [Related]
18. miR-140-5p induces cell apoptosis and decreases Warburg effect in chronic myeloid leukemia by targeting SIX1.
Nie ZY; Liu XJ; Zhan Y; Liu MH; Zhang XY; Li ZY; Lu YQ; Luo JM; Yang L
Biosci Rep; 2019 Apr; 39(4):. PubMed ID: 30962263
[TBL] [Abstract][Full Text] [Related]
19. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
[TBL] [Abstract][Full Text] [Related]
20. Dual inhibition of Bcr-Abl and Hsp90 by C086 potently inhibits the proliferation of imatinib-resistant CML cells.
Wu L; Yu J; Chen R; Liu Y; Lou L; Wu Y; Huang L; Fan Y; Gao P; Huang M; Wu Y; Chen Y; Xu J
Clin Cancer Res; 2015 Feb; 21(4):833-43. PubMed ID: 25501124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
